ISIS 721744
Sponsors
Ionis Pharmaceuticals Inc., Hospital do Coracao
Conditions
Covid19Hereditary AngioedemaHereditary Angioedema (HAE)
Phase 2
Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19
CompletedNCT04549922
Start: 2020-10-19End: 2021-12-09Updated: 2022-09-22
ISIS 721744-CS3: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema
CompletedCTIS2024-517249-15-00
Start: 2020-10-22End: 2024-12-19Target: 7Updated: 2024-11-04
Phase 3
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE).
Active, not recruitingCTIS2023-509201-77-00
Start: 2022-11-02Target: 55Updated: 2026-01-14
An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema
[Donidalorsen Treatment in Children with Hereditary Angioedema]
Not yet recruitingCTIS2025-523499-22-00
Target: 6Updated: 2026-02-26